FI3589661T3 - Her2-positiivisen rintasyövän adjuvanttihoito - Google Patents
Her2-positiivisen rintasyövän adjuvanttihoito Download PDFInfo
- Publication number
- FI3589661T3 FI3589661T3 FIEP18712044.9T FI18712044T FI3589661T3 FI 3589661 T3 FI3589661 T3 FI 3589661T3 FI 18712044 T FI18712044 T FI 18712044T FI 3589661 T3 FI3589661 T3 FI 3589661T3
- Authority
- FI
- Finland
- Prior art keywords
- pertuzumab
- trastuzumab
- chemotherapy
- administered
- administration
- Prior art date
Links
- 208000017891 HER2 positive breast carcinoma Diseases 0.000 title 1
- 238000009098 adjuvant therapy Methods 0.000 title 1
- 229960002087 pertuzumab Drugs 0.000 claims 29
- 229960000575 trastuzumab Drugs 0.000 claims 28
- 238000002512 chemotherapy Methods 0.000 claims 23
- 238000000034 method Methods 0.000 claims 16
- 206010006187 Breast cancer Diseases 0.000 claims 4
- 208000026310 Breast neoplasm Diseases 0.000 claims 4
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 4
- 229960004397 cyclophosphamide Drugs 0.000 claims 4
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 3
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 3
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 3
- 229960003668 docetaxel Drugs 0.000 claims 3
- 208000030776 invasive breast carcinoma Diseases 0.000 claims 3
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 claims 2
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 claims 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 2
- 101150054472 HER2 gene Proteins 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 229930012538 Paclitaxel Natural products 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 229960004679 doxorubicin Drugs 0.000 claims 2
- 229960001904 epirubicin Drugs 0.000 claims 2
- 108700020302 erbB-2 Genes Proteins 0.000 claims 2
- 229960002949 fluorouracil Drugs 0.000 claims 2
- 108091008039 hormone receptors Proteins 0.000 claims 2
- 229960001592 paclitaxel Drugs 0.000 claims 2
- 238000010254 subcutaneous injection Methods 0.000 claims 2
- 239000007929 subcutaneous injection Substances 0.000 claims 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 2
- 230000004544 DNA amplification Effects 0.000 claims 1
- 190000008236 carboplatin Chemical compound 0.000 claims 1
- 229960004562 carboplatin Drugs 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 238000007901 in situ hybridization Methods 0.000 claims 1
- 238000001802 infusion Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 210000001165 lymph node Anatomy 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762466239P | 2017-03-02 | 2017-03-02 | |
| US201762469317P | 2017-03-09 | 2017-03-09 | |
| US201762486876P | 2017-04-18 | 2017-04-18 | |
| PCT/US2018/020154 WO2018160654A2 (en) | 2017-03-02 | 2018-02-28 | Adjuvant treatment of her2-positive breast cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI3589661T3 true FI3589661T3 (fi) | 2024-01-31 |
Family
ID=61691568
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP18712044.9T FI3589661T3 (fi) | 2017-03-02 | 2018-02-28 | Her2-positiivisen rintasyövän adjuvanttihoito |
Country Status (22)
| Country | Link |
|---|---|
| US (5) | US11077189B2 (enExample) |
| EP (2) | EP4368199A3 (enExample) |
| JP (4) | JP6992081B2 (enExample) |
| KR (4) | KR20190096384A (enExample) |
| CN (5) | CN110337450B (enExample) |
| AU (3) | AU2018227788B2 (enExample) |
| CA (1) | CA3048918C (enExample) |
| DK (1) | DK3589661T5 (enExample) |
| ES (1) | ES2969041T3 (enExample) |
| FI (1) | FI3589661T3 (enExample) |
| HR (1) | HRP20240069T1 (enExample) |
| HU (1) | HUE064898T2 (enExample) |
| IL (3) | IL301279B2 (enExample) |
| LT (1) | LT3589661T (enExample) |
| MX (2) | MX388169B (enExample) |
| PL (1) | PL3589661T3 (enExample) |
| PT (1) | PT3589661T (enExample) |
| RS (1) | RS65204B1 (enExample) |
| SI (1) | SI3589661T1 (enExample) |
| SM (1) | SMT202400129T1 (enExample) |
| TW (3) | TWI792743B (enExample) |
| WO (1) | WO2018160654A2 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ517150A (en) * | 1999-08-27 | 2005-01-28 | Genentech Inc | Dosages for treatment with anti-ErbB2 antibodies |
| TWI472339B (zh) | 2008-01-30 | 2015-02-11 | Genentech Inc | 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物 |
| BRPI0812682A2 (pt) | 2008-06-16 | 2010-06-22 | Genentech Inc | tratamento de cáncer de mama metastático |
| US9345661B2 (en) | 2009-07-31 | 2016-05-24 | Genentech, Inc. | Subcutaneous anti-HER2 antibody formulations and uses thereof |
| RU2737727C2 (ru) | 2013-04-16 | 2020-12-02 | Дженентек, Инк. | Варианты пертузумаба и их аналитическая характеристика |
| US10380152B2 (en) * | 2016-01-19 | 2019-08-13 | International Business Machines Corporation | Cognitive system comparison and recommendation engine |
| MY189536A (en) | 2017-01-17 | 2022-02-16 | Hoffmann La Roche | Subcutaneous her2 antibody formulations |
| KR20190096384A (ko) | 2017-03-02 | 2019-08-19 | 제넨테크, 인크. | Her2-양성 유방암 어쥬번트 치료 |
| US12371683B2 (en) | 2018-07-25 | 2025-07-29 | Alteogen Inc. | Hyaluronidase variants and pharmaceutical composition comprising the same |
| BR112021019076A2 (pt) * | 2019-03-25 | 2021-11-30 | Alteogen Inc | Composição farmacêutica e formulação para injeção subcutânea compreendendo uma variante de hialuronidase ph20 humana |
| WO2020205807A1 (en) * | 2019-03-29 | 2020-10-08 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of treatments based upon anthracycline responsiveness |
| CN113924116B (zh) * | 2019-05-02 | 2025-11-25 | Mab发现股份有限公司 | Her2抗体的组合 |
| IL298538A (en) * | 2020-05-29 | 2023-01-01 | Seagen Inc | Methods of treating her2 positive cancer with tucatinib in combination with trastuzumab and an oxaliplatin-based chemotherapy |
| CN115916834A (zh) * | 2020-06-29 | 2023-04-04 | 基因泰克公司 | 帕妥珠单抗加曲妥珠单抗的固定剂量组合 |
| AU2021320569B2 (en) | 2020-08-07 | 2024-10-03 | Alteogen, Inc | Method for producing recombinant hyaluronidase |
| CN113943805A (zh) * | 2021-11-02 | 2022-01-18 | 上海市生物医药技术研究院 | 基因突变检测引物组及其用途 |
| CN117224689B (zh) * | 2023-11-16 | 2024-02-23 | 上海复宏汉霖生物技术股份有限公司 | 联合抗her2抗体和化疗剂治疗胃癌的用途 |
Family Cites Families (131)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| WO1985003357A1 (en) | 1984-01-30 | 1985-08-01 | Icrf Patents Ltd. | Improvements relating to growth factors |
| US5401638A (en) | 1986-06-04 | 1995-03-28 | Oncogene Science, Inc. | Detection and quantification of neu related proteins in the biological fluids of humans |
| US4968603A (en) | 1986-12-31 | 1990-11-06 | The Regents Of The University Of California | Determination of status in neoplastic disease |
| CA1339946C (en) | 1987-03-31 | 1998-07-07 | Michael J. Griffith | Ultrapurification process for polypeptides |
| US5824311A (en) | 1987-11-30 | 1998-10-20 | Trustees Of The University Of Pennsylvania | Treatment of tumors with monoclonal antibodies against oncogene antigens |
| US5720937A (en) | 1988-01-12 | 1998-02-24 | Genentech, Inc. | In vivo tumor detection assay |
| WO1989006692A1 (en) | 1988-01-12 | 1989-07-27 | Genentech, Inc. | Method of treating tumor cells by inhibiting growth factor receptor function |
| WO1990014357A1 (en) | 1989-05-19 | 1990-11-29 | Genentech, Inc. | Her2 extracellular domain |
| EP0494135B1 (en) | 1989-09-29 | 1996-04-10 | Oncogene Science, Inc. | Human "neu" related protein p100 and use of the same for detecting preneoplastic or neoplastic cells in a human |
| US5183884A (en) | 1989-12-01 | 1993-02-02 | United States Of America | Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor |
| IL101943A0 (en) | 1991-05-24 | 1992-12-30 | Genentech Inc | Structure,production and use of heregulin |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| EP0940468A1 (en) | 1991-06-14 | 1999-09-08 | Genentech, Inc. | Humanized antibody variable domain |
| US6800738B1 (en) | 1991-06-14 | 2004-10-05 | Genentech, Inc. | Method for making humanized antibodies |
| EP0604580A1 (en) | 1991-09-19 | 1994-07-06 | Genentech, Inc. | EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES |
| SI1516628T1 (sl) | 1995-07-27 | 2013-10-30 | Genentech, Inc. | Stabilna izotonična liofilizirana proteinska formulacija |
| US6685940B2 (en) | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| US5783186A (en) | 1995-12-05 | 1998-07-21 | Amgen Inc. | Antibody-induced apoptosis |
| US7371376B1 (en) | 1996-10-18 | 2008-05-13 | Genentech, Inc. | Anti-ErbB2 antibodies |
| EP0852951A1 (de) | 1996-11-19 | 1998-07-15 | Roche Diagnostics GmbH | Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern |
| ES2335365T3 (es) | 1996-11-27 | 2010-03-25 | Genentech, Inc. | Purificacion por afinidad de polipeptido en una matriz de proteina a. |
| US5994071A (en) | 1997-04-04 | 1999-11-30 | Albany Medical College | Assessment of prostate cancer |
| ZA9811162B (en) | 1997-12-12 | 2000-06-07 | Genentech Inc | Treatment with anti-ERBB2 antibodies. |
| IL138034A0 (en) | 1998-03-27 | 2001-10-31 | Genentech Inc | Apo-2 ligand-anti-her-2 antibody synergism |
| KR20010043323A (ko) | 1998-05-06 | 2001-05-25 | 제넨테크, 인크. | 이온 교환 크로마토그래피에 의한 단백질 정제 방법 |
| US6573043B1 (en) | 1998-10-07 | 2003-06-03 | Genentech, Inc. | Tissue analysis and kits therefor |
| AU782325B2 (en) | 1999-05-14 | 2005-07-21 | Genentech Inc. | Treatment with anti-ErbB2 antibodies |
| PT1189634E (pt) | 1999-06-25 | 2007-06-06 | Genentech Inc | Tratamento de cancro da próstata com anticorpos anti-erbb2. |
| US6949245B1 (en) | 1999-06-25 | 2005-09-27 | Genentech, Inc. | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
| US20040013667A1 (en) | 1999-06-25 | 2004-01-22 | Genentech, Inc. | Treatment with anti-ErbB2 antibodies |
| US20030086924A1 (en) | 1999-06-25 | 2003-05-08 | Genentech, Inc. | Treatment with anti-ErbB2 antibodies |
| US7041292B1 (en) | 1999-06-25 | 2006-05-09 | Genentech, Inc. | Treating prostate cancer with anti-ErbB2 antibodies |
| KR100850389B1 (ko) | 1999-06-25 | 2008-08-04 | 제넨테크, 인크. | 인간화 항-ＥｒｂＢ2 항체 및 항-ＥｒｂＢ2 항체를 사용한치료 방법 |
| NZ517150A (en) | 1999-08-27 | 2005-01-28 | Genentech Inc | Dosages for treatment with anti-ErbB2 antibodies |
| US6632979B2 (en) | 2000-03-16 | 2003-10-14 | Genentech, Inc. | Rodent HER2 tumor model |
| US7097840B2 (en) | 2000-03-16 | 2006-08-29 | Genentech, Inc. | Methods of treatment using anti-ErbB antibody-maytansinoid conjugates |
| US20200048362A1 (en) | 2000-03-16 | 2020-02-13 | Immunogen, Inc. | Methods of treatment using anti-erbb antibody-maytansinoid conjugates |
| EP1282443B1 (en) | 2000-05-19 | 2009-09-02 | Genentech, Inc. | Gene detection assay for improving the likelihood of an effective response to an erbb antagonist cancer therapy |
| US20030232399A1 (en) | 2000-06-14 | 2003-12-18 | Robertson John Forsyth Russell | Cancer detection methods and reagents |
| US6984494B2 (en) | 2000-08-15 | 2006-01-10 | Genentech, Inc. | Analytical method |
| JP4731793B2 (ja) | 2000-12-28 | 2011-07-27 | アルセア テクノロジーズ インコーポレイテッド | 抗体全体またはそのフラグメントの結晶、ならびにこの結晶を作製および使用するための方法 |
| US6695940B2 (en) | 2001-04-05 | 2004-02-24 | Alan D. Devoe | Laminate thin-wall ceramic tubes, including with integral stress wrappings, thickened ends and/or internal baffles, particularly for solid oxide fuel cells |
| WO2003013434A2 (en) | 2001-08-06 | 2003-02-20 | Genomed, Llc | Methods and compositions for treating diseases associated with excesses in ace |
| EP1300146A1 (en) | 2001-10-03 | 2003-04-09 | Boehringer Ingelheim International GmbH | Pharmaceutical composition for the treatment of animal mammary tumors |
| US20040048525A1 (en) | 2002-01-28 | 2004-03-11 | Sagucio Esteban N. | Watercycle for wet rider |
| US7435797B2 (en) | 2002-04-10 | 2008-10-14 | Genentech, Inc. | Anti-HER2 antibody variants |
| UA81628C2 (uk) | 2002-05-17 | 2008-01-25 | Авентіс Фарма С.А. | Застосування доцетакселу/доксорубіцину/циклофосфаміду у допоміжній терапії раку молочної залози |
| WO2004008099A2 (en) | 2002-07-15 | 2004-01-22 | Genentech, Inc. | METHODS FOR IDENTIFYING TUMORS THAT ARE RESPONSIVE TO TREATMENT WITH ANTI-ErbB2 ANTIBODIES |
| US6982719B2 (en) | 2002-07-15 | 2006-01-03 | Sun Microsystems, Inc. | Switching sample buffer context in response to sample requests for real-time sample filtering and video generation |
| US7129840B2 (en) | 2002-09-03 | 2006-10-31 | Ricoh Company, Ltd. | Document security system |
| CA2496060C (en) | 2002-09-11 | 2015-08-04 | Genentech, Inc. | Protein purification by ion exchange chromatography |
| US20060100168A1 (en) | 2002-09-30 | 2006-05-11 | The Trustee Of Boston University | Method of treating cancer using adenosine and its analogs |
| EP1572972A4 (en) | 2002-11-21 | 2007-11-21 | Genentech Inc | THERAPY OF NON-MALIGNER DISEASES OR DISORDER WITH ANTI-ERBB2 ANTIBODIES |
| US20050158303A1 (en) | 2003-04-04 | 2005-07-21 | Genentech, Inc. | Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations |
| US20050025753A1 (en) | 2003-04-30 | 2005-02-03 | Wei Han | Methods for production of non-disease causing hemoglobin by ex vivo oligonucleotide gene editing of human stem/progenitor cells |
| JP4599355B2 (ja) | 2003-07-28 | 2010-12-15 | ジェネンテック， インコーポレイテッド | プロテインａアフィニティークロマトグラフィーの間のプロテインａの浸出の低減 |
| JP4969440B2 (ja) | 2004-04-08 | 2012-07-04 | デビッド， ビー． エイガス， | 疼痛治療のためのＥｒｂＢアンタゴニスト |
| AU2005249360B2 (en) | 2004-04-12 | 2011-07-21 | Medimmune, Llc | Anti-IL-9 antibody formulations and uses thereof |
| US7195440B2 (en) | 2004-05-27 | 2007-03-27 | Lambert Charles F | Agricultural silo auger system apparatus and method |
| BRPI0510883B8 (pt) | 2004-06-01 | 2021-05-25 | Genentech Inc | composto conjugado de droga e anticorpo, composição farmacêutica, método de fabricação de composto conjugado de droga e anticorpo e usos de uma formulação, de um conjugado de droga e anticorpo e um agente quimioterapêutico e de uma combinação |
| GT200500155A (es) | 2004-06-16 | 2006-05-15 | Terapia del càncer resistente al platino | |
| KR20110050567A (ko) | 2004-07-22 | 2011-05-13 | 제넨테크, 인크. | Ｈｅｒ２ 항체 조성물 |
| US20060067930A1 (en) | 2004-08-19 | 2006-03-30 | Genentech, Inc. | Polypeptide variants with altered effector function |
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| EP1819735A1 (en) | 2004-11-04 | 2007-08-22 | Pfizer Products Inc. | Ctla-4 antibody and aromatase inhibitor or combination treatment for breast cancer |
| WO2006063042A2 (en) | 2004-12-07 | 2006-06-15 | Genentech, Inc. | Selecting patients for therapy with a her inhibitor |
| TWI441646B (zh) | 2005-01-21 | 2014-06-21 | Genentech Inc | 帕妥珠單抗(pertuzumab)用於製備治療人類病患癌症之藥物的用途 |
| CA2598239C (en) | 2005-02-18 | 2019-10-29 | Abraxis Bioscience, Inc. | Nanoparticulate formulations of taxanes and carrier proteins for use in combination chemotherapy |
| CA2596133C (en) | 2005-02-23 | 2016-11-15 | Genentech, Inc. | Extending time to disease progression or survival in cancer patients |
| TW200642695A (en) | 2005-03-08 | 2006-12-16 | Genentech Inc | Methods for identifying tumors responsive to treatment with her dimerization inhibitors (HDIs) |
| US20060212956A1 (en) | 2005-03-14 | 2006-09-21 | Genentech, Inc. | Animal model of ligand activated HER2 expressing tumors |
| JP2006316040A (ja) | 2005-05-13 | 2006-11-24 | Genentech Inc | Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法 |
| US20070009976A1 (en) | 2005-07-06 | 2007-01-11 | Helmut Lenz | Detection of a target antigen irrespective of the presence or absence of a corresponding therapeutic antibody |
| PE20070207A1 (es) | 2005-07-22 | 2007-03-09 | Genentech Inc | Tratamiento combinado de los tumores que expresan el her |
| US7700299B2 (en) | 2005-08-12 | 2010-04-20 | Hoffmann-La Roche Inc. | Method for predicting the response to a treatment |
| CA2631981A1 (en) | 2005-12-05 | 2007-06-14 | Trinity Biosystems, Inc. | Methods and compositions for needleless delivery of binding partners |
| TW200812615A (en) | 2006-03-22 | 2008-03-16 | Hoffmann La Roche | Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2 |
| AU2007254950A1 (en) | 2006-05-31 | 2007-12-13 | Thallion Pharmaceuticals Incorporated | Methods, compositions, and kits for treating Shiga toxin associated conditions |
| JP2009539836A (ja) | 2006-06-05 | 2009-11-19 | ジェネンテック・インコーポレーテッド | ＥＧＦまたはＴＧＦ−αのレベルの上昇が生じている癌患者の生存の延長 |
| WO2008022746A1 (en) | 2006-08-21 | 2008-02-28 | F. Hoffmann-La Roche Ag | Tumor therapy with an anti-vegf antibody |
| WO2008031531A1 (en) * | 2006-09-15 | 2008-03-20 | F. Hoffmann-La Roche Ag | Tumor therapy with a combination of anti-her2 antibodies |
| PL2132573T3 (pl) | 2007-03-02 | 2014-09-30 | Genentech Inc | Prognozowanie odpowiedzi na inhibitor dimeryzacji HER oparte na niskiej ekspresji HER3 |
| EP1997534A1 (en) | 2007-05-31 | 2008-12-03 | Pierre Fabre Medicament | Cancer treatment combination therapy comprising vinflunine and trastuzumab |
| EP2155786B1 (en) | 2007-06-06 | 2015-11-18 | F. Hoffmann-La Roche AG | Composition of a first non-labeled monoclonal antibody binding to a tumor antigen and a non-cross reactive second monoclonal antibody labeled with a nir fluorescence label |
| EP2171090B1 (en) | 2007-06-08 | 2013-04-03 | Genentech, Inc. | Gene expression markers of tumor resistance to her2 inhibitor treatment |
| US9551033B2 (en) | 2007-06-08 | 2017-01-24 | Genentech, Inc. | Gene expression markers of tumor resistance to HER2 inhibitor treatment |
| CA2699202C (en) | 2007-09-12 | 2016-09-27 | F. Hoffmann-La Roche Ag | Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use |
| CN101903025A (zh) | 2007-10-19 | 2010-12-01 | 彼帕科学公司 | 利用苯并吡喃酮-型parp抑制剂治疗癌症的方法和组合物 |
| PE20091434A1 (es) | 2007-10-30 | 2009-10-17 | Genentech Inc | Purificacion de anticuerpos por cromatografia de intercambio cationico |
| NZ586125A (en) | 2007-11-12 | 2012-12-21 | Bipar Sciences Inc | Treatment of breast cancer with a parp inhibitor alone or in combination with anti-tumor agents |
| TWI472339B (zh) | 2008-01-30 | 2015-02-11 | Genentech Inc | 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物 |
| US20090203015A1 (en) | 2008-02-13 | 2009-08-13 | Celera Corporation | Multiplex assays for hormonal and growth factor receptors, and uses thereof |
| AU2009221729A1 (en) | 2008-03-06 | 2009-09-11 | Genentech, Inc. | Combination therapy with c-met and HER antagonists |
| MY166445A (en) | 2008-03-18 | 2018-06-27 | Genentech Inc | Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents,and methods of use |
| US9235334B2 (en) | 2008-05-09 | 2016-01-12 | Genesis Industries, Llc | Managing landbases and machine operations performed thereon |
| BRPI0812682A2 (pt) | 2008-06-16 | 2010-06-22 | Genentech Inc | tratamento de cáncer de mama metastático |
| US8216997B2 (en) | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
| WO2010042705A1 (en) | 2008-10-09 | 2010-04-15 | Medimmune, Llc | Antibody formulation |
| KR20170015525A (ko) | 2008-11-22 | 2017-02-08 | 제넨테크, 인크. | 유방암의 치료를 위한, 화학요법과 조합된 항-ｖｅｇｆ 항체의 용도 |
| JP2012519712A (ja) | 2009-03-06 | 2012-08-30 | メディミューン，エルエルシー | ヒト化抗ｃｄ１９抗体製剤 |
| EP2435071A1 (en) | 2009-05-29 | 2012-04-04 | F. Hoffmann-La Roche AG | Modulators for her2 signaling in her2 expressing patients with gastric cancer |
| US9345661B2 (en) | 2009-07-31 | 2016-05-24 | Genentech, Inc. | Subcutaneous anti-HER2 antibody formulations and uses thereof |
| WO2011036280A1 (en) | 2009-09-28 | 2011-03-31 | F. Hoffmann-La Roche Ag | Benzoxazepin pi3k inhibitor compounds and methods of use |
| US20110165155A1 (en) | 2009-12-04 | 2011-07-07 | Genentech, Inc. | Methods of treating metastatic breast cancer with trastuzumab-mcc-dm1 |
| WO2011146568A1 (en) | 2010-05-19 | 2011-11-24 | Genentech, Inc. | Predicting response to a her inhibitor |
| JP2014502596A (ja) | 2010-12-09 | 2014-02-03 | ジェネンテック， インコーポレイテッド | パクリタキセルおよびトラスツズマブ−ｍｃｃ−ｄｍ１を用いたｈｅｒ２陽性癌の治療 |
| EP2683413A1 (en) | 2011-03-07 | 2014-01-15 | F.Hoffmann-La Roche Ag | In vivo selection of therapeutically active antibodies |
| FI4241849T3 (fi) | 2011-10-14 | 2024-11-12 | Hoffmann La Roche | Her2:n dimerisaation estäjä pertutsumabin käyttötapoja ja sitä sisältävä tuote |
| WO2013083810A1 (en) | 2011-12-09 | 2013-06-13 | F. Hoffmann-La Roche Ag | Identification of non-responders to her2 inhibitors |
| US20130195851A1 (en) | 2011-12-23 | 2013-08-01 | Genentech, Inc. | Articles of manufacture and methods for co-administration of antibodies |
| SG10201706196XA (en) | 2012-06-08 | 2017-08-30 | Hoffmann La Roche | Mutant selectivity and combinations of a phosphoinositide 3 kinase inhibitor compound and chemotherapeutic agents for the treatment of cancer |
| HK1206605A1 (en) | 2012-08-17 | 2016-01-15 | 霍夫曼-拉罗奇有限公司 | Combination therapies for melanoma comprising administering cobimetinib and vemurafinib |
| RU2692773C2 (ru) | 2012-11-30 | 2019-06-27 | Ф.Хоффманн-Ля Рош Аг | Идентификация пациентов, нуждающихся в совместной терапии с использованием ингибитора pd-l1 |
| AR094403A1 (es) | 2013-01-11 | 2015-07-29 | Hoffmann La Roche | Terapia de combinación de anticuerpos anti-her3 |
| RU2737727C2 (ru) | 2013-04-16 | 2020-12-02 | Дженентек, Инк. | Варианты пертузумаба и их аналитическая характеристика |
| MY189089A (en) | 2013-12-17 | 2022-01-25 | Genentech Inc | Methods of treating cancers using pd-1 axis binding antagonists and taxanes |
| RU2020120593A (ru) * | 2014-04-25 | 2020-09-01 | Дженентек, Инк. | Способы лечения раннего рака молочной железы трастузумабом-mcc-dm1 и пертузумабом |
| LT3319995T (lt) | 2015-07-07 | 2019-07-10 | F. Hoffmann-La Roche Ag | Sudėtinis gydymas anti-her-2 antikūno-vaisto konjugatu ir bcl-2 inhibitoriumi |
| WO2017087280A1 (en) | 2015-11-16 | 2017-05-26 | Genentech, Inc. | Methods of treating her2-positive cancer |
| FR3056576B1 (fr) | 2016-09-29 | 2020-02-07 | Easyl | Procede de fabrication de diglyceroxyde de calcium |
| CN110505880A (zh) * | 2016-11-04 | 2019-11-26 | 基因泰克公司 | Her2阳性乳腺癌的治疗 |
| AU2017387909A1 (en) | 2016-12-28 | 2019-06-27 | Genentech, Inc. | Treatment of advanced HER2 expressing cancer |
| MY189536A (en) | 2017-01-17 | 2022-02-16 | Hoffmann La Roche | Subcutaneous her2 antibody formulations |
| KR20190096384A (ko) | 2017-03-02 | 2019-08-19 | 제넨테크, 인크. | Her2-양성 유방암 어쥬번트 치료 |
| TW201927288A (zh) | 2017-10-20 | 2019-07-16 | 德商拜恩迪克Ｒｎａ製藥有限公司 | 適用於治療之微脂體ｒｎａ配製物的製備及儲存 |
| CN115916834A (zh) | 2020-06-29 | 2023-04-04 | 基因泰克公司 | 帕妥珠单抗加曲妥珠单抗的固定剂量组合 |
| JP2023533813A (ja) | 2020-07-14 | 2023-08-04 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | 一定用量配合剤のアッセイ |
| EP4259662A1 (en) | 2020-12-11 | 2023-10-18 | Genentech, Inc. | Combination therapies for treatment of her2 cancer |
| IL315153A (en) | 2022-03-14 | 2024-10-01 | Genentech Inc | Combined treatments for breast cancer |
-
2018
- 2018-02-28 KR KR1020197020413A patent/KR20190096384A/ko not_active Ceased
- 2018-02-28 EP EP23205007.0A patent/EP4368199A3/en active Pending
- 2018-02-28 KR KR1020237033237A patent/KR20230144110A/ko not_active Ceased
- 2018-02-28 LT LTEPPCT/US2018/020154T patent/LT3589661T/lt unknown
- 2018-02-28 HU HUE18712044A patent/HUE064898T2/hu unknown
- 2018-02-28 MX MX2019010296A patent/MX388169B/es unknown
- 2018-02-28 CN CN201880014322.8A patent/CN110337450B/zh active Active
- 2018-02-28 CA CA3048918A patent/CA3048918C/en active Active
- 2018-02-28 IL IL301279A patent/IL301279B2/en unknown
- 2018-02-28 KR KR1020217027734A patent/KR102417583B1/ko active Active
- 2018-02-28 US US15/907,718 patent/US11077189B2/en active Active
- 2018-02-28 IL IL289297A patent/IL289297B2/en unknown
- 2018-02-28 CN CN202310488287.6A patent/CN116531511A/zh active Pending
- 2018-02-28 JP JP2019547135A patent/JP6992081B2/ja active Active
- 2018-02-28 PT PT187120449T patent/PT3589661T/pt unknown
- 2018-02-28 ES ES18712044T patent/ES2969041T3/es active Active
- 2018-02-28 HR HRP20240069TT patent/HRP20240069T1/hr unknown
- 2018-02-28 AU AU2018227788A patent/AU2018227788B2/en active Active
- 2018-02-28 DK DK18712044.9T patent/DK3589661T5/da active
- 2018-02-28 CN CN202311196502.1A patent/CN117180422A/zh active Pending
- 2018-02-28 SM SM20240129T patent/SMT202400129T1/it unknown
- 2018-02-28 RS RS20240083A patent/RS65204B1/sr unknown
- 2018-02-28 SI SI201831055T patent/SI3589661T1/sl unknown
- 2018-02-28 KR KR1020227022617A patent/KR20220100996A/ko not_active Ceased
- 2018-02-28 CN CN202310813342.4A patent/CN116850283A/zh active Pending
- 2018-02-28 PL PL18712044.9T patent/PL3589661T3/pl unknown
- 2018-02-28 WO PCT/US2018/020154 patent/WO2018160654A2/en not_active Ceased
- 2018-02-28 EP EP18712044.9A patent/EP3589661B1/en active Active
- 2018-02-28 CN CN202210489702.5A patent/CN114984206A/zh not_active Withdrawn
- 2018-02-28 FI FIEP18712044.9T patent/FI3589661T3/fi active
- 2018-03-01 TW TW110145536A patent/TWI792743B/zh active
- 2018-03-01 TW TW112106134A patent/TWI831617B/zh active
- 2018-03-01 TW TW107106709A patent/TWI748062B/zh active
-
2019
- 2019-07-31 IL IL268394A patent/IL268394B2/en unknown
- 2019-08-29 MX MX2021014137A patent/MX2021014137A/es unknown
-
2021
- 2021-07-09 US US17/305,556 patent/US11992529B2/en active Active
- 2021-07-15 AU AU2021205081A patent/AU2021205081B2/en active Active
- 2021-10-26 JP JP2021174654A patent/JP7270701B2/ja active Active
-
2022
- 2022-08-22 US US17/821,270 patent/US11638756B2/en active Active
-
2023
- 2023-02-07 JP JP2023016713A patent/JP2023071672A/ja active Pending
- 2023-09-25 JP JP2023160008A patent/JP2024001062A/ja active Pending
- 2023-10-02 AU AU2023237217A patent/AU2023237217B2/en active Active
-
2024
- 2024-04-16 US US18/637,283 patent/US12128103B2/en active Active
- 2024-09-23 US US18/893,603 patent/US20250018032A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI3589661T3 (fi) | Her2-positiivisen rintasyövän adjuvanttihoito | |
| FI4403228T3 (fi) | Her2:n dimerisaation estäjä pertutsumabin käyttötapoja ja sitä sisältävä tuote | |
| JP2020509024A5 (enExample) | ||
| Berretta et al. | Feasibility of intraperitoneal Trastuzumab treatment in a patient with peritoneal carcinomatosis from gastric cancer | |
| Nelson et al. | Phase 1b study of combined selinexor and eribulin for the treatment of advanced solid tumors and triple‐negative breast cancer | |
| US9415078B2 (en) | Method of treating desmocollin-3 expressing cancer with Mycobacterium w | |
| JP6489517B2 (ja) | ガン幹細胞に対する分化促進薬及び脳腫瘍治療薬 | |
| CN105147654A (zh) | 一种将白藜芦醇和二甲双胍组合用于抗肿瘤药物 | |
| RU2524309C1 (ru) | Способ выбора тактики лечения местно-распространенного рака предстательной железы | |
| Weissinger et al. | Successful treatment of a patient with HER2-positive metastatic gastric cancer with third-line combination therapy with irinotecan, 5-fluorouracil, leucovorin and trastuzumab (FOLFIRI-T) | |
| TWI798243B (zh) | 治療癌症的方法 | |
| Ettorre et al. | Distal pancreatectomy with splenorenal shunt to preserve spleen in a cirrhotic patient | |
| Leon-Ferre et al. | Extravasation of oxaliplatin into the mediastinum: a case report and review of the literature | |
| Ottone et al. | A case of long-term survival after repeated response to oxaliplatin-based chemotherapy and repeated thermoablation of liver metastases from colorectal cancer. Should we introduce the concept of oxaliplatin-resistant tumors? | |
| Ibrahim et al. | BP-C2 improves functional status, quality of life and corrects biochemical imbalances as adjuvant therapy to FOLFIRINOX treatment: A case of advanced inoperable pancreatic cancer | |
| Spilman et al. | P3. 18.53 Phase 3 Clinical Trial ResQ201A of N-803 (NAI), Tislelizumab and Docetaxel Vs. Docetaxel Monotherapy for Advanced NSCLC Resistant to ICI Therapy | |
| Okamoto | Bevacizumab/paclitaxel | |
| Zhao et al. | 133TiP An open label pilot study to evaluate efficacy and safety of durvalumab with hepatic artery infusion chemotherapy (HAIC) in advanced hepatocellular (aHCC) patients with severe portal vein tumor thrombosis (PVTT)(Vp3 and/or Vp4): DurHope | |
| Ryu et al. | Pancreaticoduodenectomy for advanced gastric carcinoma patients | |
| Lambert | Biological drugs in breast cancer: increasing understanding for the pharmacist | |
| JP2016017059A (ja) | 抗腫瘍性プロドラッグを含む組成物 | |
| Zhou et al. | PCN96 Cost Minimization Analysis of Xeloda® Versus 5-Fluorouracil-Based Treatment for Gastric Cancer Patients in Hong Kong | |
| Muto | Carboplatin/paclitaxel | |
| MOON | Sipuleucel-T Prolongs Survival in Prostate Cancer | |
| Burudpakdee et al. | PCN94 Feasibility of Efficiency Frontier Analysis (EFA) in Metastatic Breast Cancer (mBC) Treatments: A UK Perspective |